Glycopyrronium Cantabria (Glycopyrronium)

Glycopyrronium Cantabria is primarily indicated for the management of primary axillary hyperhidrosis, a condition characterized by excessive under‑arm sweating.

• Reduces sweat production in the under‑arm region when applied as directed.
• May be used as an alternative to oral anticholinergics for localized treatment.
• Can be considered for patients who have not responded adequately to topical aluminum‑based antiperspirants.
• Suitable for adults and adolescents when prescribed by a healthcare professional.
• May improve quality‑of‑life measures related to social and occupational activities.

The safety profile of Glycopyrronium Cantabria includes both frequently observed and less common adverse reactions.

Common

• Transient skin irritation or erythema at the application site.
• Mild pruritus or itching where the product is applied.
• Dryness of the treated skin.
• Temporary reduction in local sweating that may be perceived as excessive dryness.

Serious

• Allergic contact dermatitis presenting with swelling, blistering, or severe rash.
• Systemic anticholinergic effects such as dry mouth, blurred vision, or urinary retention, especially if applied over large areas.
• Unexpected tachycardia or palpitations.
• Severe skin necrosis (rare).

Before initiating therapy with Glycopyrronium Cantabria, certain precautions and warnings should be considered.

• Avoid application to broken, inflamed, or infected skin.
• Do not use on areas other than the axillae unless directed by a clinician.
• Patients with narrow‑angle glaucoma or urinary retention should discuss use with their physician.
• Pregnant or breastfeeding individuals should be evaluated for potential risks, as safety data are limited.
• Concomitant use with other topical anticholinergics may increase local adverse effects.
• Keep the product out of reach of children; accidental ingestion can cause systemic anticholinergic toxicity.
• Discontinue use and seek medical advice if severe skin reactions develop.

Glycopyrronium Cantabria may interact with other medications or substances that influence anticholinergic activity.

Avoid

• Concurrent use of systemic anticholinergic drugs (e.g., atropine, scopolamine) that could amplify anticholinergic side effects.
• Application together with other topical agents containing anticholinergic compounds.

Use with caution

• Beta‑blockers or antihypertensive agents if systemic absorption leads to cardiovascular effects.
• Drugs that affect sweating regulation, such as certain antidepressants or antipsychotics.
• Alcohol or sedatives, which may exacerbate dry mouth or blurred vision.